Insider Trading February 24, 2026

Murphy USA SVP Disposes $1.1 Million in Stock; Company Posts Mixed Q4 Results

Renee M. Bacon sold 2,844 shares while recent quarterly results showed EPS outperformance but revenue shortfall and divergent analyst reactions

By Jordan Park MUSA
Murphy USA SVP Disposes $1.1 Million in Stock; Company Posts Mixed Q4 Results
MUSA

Renee M. Bacon, senior vice president for sales and operations at Murphy USA Inc. (NYSE: MUSA), executed a sale of 2,844 shares on February 23, 2026, generating roughly $1.105 million. The transaction, recorded in a Form 4 filing with the Securities and Exchange Commission, leaves Bacon with a direct holding of 3,083.3 shares. Separately, Murphy USA reported fourth-quarter 2025 results that beat EPS expectations but missed on revenue, prompting differing analyst target adjustments.

Key Points

  • Renee M. Bacon sold 2,844 shares on February 23, 2026 at $388.61 per share for a total of $1.105 million; post-sale direct holdings are 3,083.3 shares - impacts equity ownership disclosure and insider activity monitoring.
  • Murphy USA reported Q4 2025 EPS of $7.53, beating a $6.45 forecast, while revenue of $4.74 billion missed an expected $4.88 billion - highlights mixed financial performance.
  • Analysts diverged after results: KeyBanc raised its price target to $500 and stayed Overweight citing strong earnings from higher fuel margins, while Stephens lowered its target to $450 but maintained an Overweight rating, noting an above-expectations EBITDA of $290.9 million.

Transaction details

Renee M. Bacon, who serves as senior vice president of sales and operations at Murphy USA Inc. (NYSE: MUSA), sold 2,844 shares of the companys common stock on February 23, 2026. The sale was executed at $388.61 per share, producing a gross transaction value of approximately $1.105 million. The disposition was publicly disclosed in a Form 4 filing submitted to the Securities and Exchange Commission. Following the sale, Bacon directly holds 3,083.3 shares of Murphy USA common stock.

Context from corporate results and market commentary

In corporate reporting, Murphy USA released its fourth-quarter 2025 financial results in which reported earnings per share were $7.53, exceeding the forecasted $6.45. Revenue for the quarter totaled $4.74 billion, below the $4.88 billion that analysts had anticipated. These mixed results have led to differing analyst reactions.

Analyst moves

KeyBanc Capital Markets moved to raise its price target to $500 and kept an Overweight rating, pointing to strong earnings performance driven by higher fuel margins. In contrast, Stephens reduced its price target to $450 while maintaining an Overweight rating, citing a softer outlook for 2026 despite noting that Murphy USA reported EBITDA of $290.9 million, which outpaced both Stephens own forecast and consensus expectations.

Other market notes

Separately, a market analysis included with the transaction reporting observed that Murphy USA appears undervalued at current levels. The same commentary noted that company management has been active in repurchasing shares. Additionally, a comprehensive research report covering this company is available alongside coverage for more than 1,400 U.S. equities, according to the disclosure accompanying the analysis.


Takeaway

The insider sale by a senior operations executive and the companys mixed quarterly performance - EPS above expectations but revenue below - come amid ongoing share repurchase activity and divergent analyst price-target adjustments. The net effect on investor sentiment will depend on how market participants weigh the earnings beat, revenue shortfall, and the differing analyst outlooks.

Risks

  • Insider selling may be interpreted negatively by some investors, potentially affecting short-term equity sentiment - impacts equity markets and investor confidence.
  • A revenue shortfall despite an EPS beat introduces uncertainty around top-line growth and demand assumptions heading into 2026 - impacts corporate revenue forecasts and sector valuations.
  • Divergent analyst views and differing price targets create mixed signals for market participants, which could increase volatility in the companys shares as investors reconcile competing assessments.

More from Insider Trading

ImmunityBio Director Sells $250,000 in Stock as Company Posts Strong ANKTIVA Revenue Gains Feb 24, 2026 Palantir CEO Disposes $65.9M of Class A Shares, Converts Class B Stock Amid Corporate Momentum Feb 24, 2026 Palantir Director Sells $43.7M in Class A Shares as Stock Trades Below Peak Levels Feb 24, 2026 ImmunityBio Director Executes $1.78M Stock Sales as ANKTIVA Revenue Accelerates Feb 24, 2026 KalVista CFO Disposes $27,506 in Stock as Company Posts Strong EKTERLY Launch Metrics Feb 24, 2026